The article discusses current concepts in assessing fracture risk in osteoporosis. Bone mineral density (BMD) is the standard for diagnosing osteoporosis and assessing fracture risk. The Fracture Risk Assessment Tool (FRAX) is used to predict fracture risk based on clinical risk factors, including BMD. Treatment for osteoporosis is recommended for patients with low BMD or a high fracture risk as determined by FRAX. Biochemical bone markers can help monitor treatment effectiveness and identify high-risk patients. Osteoporosis is a common metabolic bone disease affecting up to 40% of postmenopausal women. It is often asymptomatic, and many fractures go unrecognized. FRAX is a tool that considers clinical risk factors and BMD to assess fracture risk. It is used to determine when treatment is needed, especially for patients with a T-score between -1.0 and -2.5 and a high fracture risk. FRAX has been validated in various countries and is available online. Bone mineral density is measured using dual x-ray absorptiometry, but it has limitations. It does not account for bone geometry or microarchitecture. Other factors, such as age, history of fractures, and lifestyle, also contribute to fracture risk. FRAX incorporates these factors to improve fracture risk prediction. Bone turnover markers, such as bone resorption and formation markers, are used to assess bone health and monitor treatment effectiveness. These markers can help identify patients at higher risk of fractures. However, FRAX may not accurately predict fracture risk in all age groups or for all patients. The article emphasizes the importance of combining clinical risk factors, BMD, and bone turnover markers to improve fracture risk assessment. It also highlights the limitations of FRAX, including potential inaccuracies in predicting fracture risk and the need for further research. Overall, the assessment of fracture risk is crucial for effective osteoporosis management and prevention of fractures.The article discusses current concepts in assessing fracture risk in osteoporosis. Bone mineral density (BMD) is the standard for diagnosing osteoporosis and assessing fracture risk. The Fracture Risk Assessment Tool (FRAX) is used to predict fracture risk based on clinical risk factors, including BMD. Treatment for osteoporosis is recommended for patients with low BMD or a high fracture risk as determined by FRAX. Biochemical bone markers can help monitor treatment effectiveness and identify high-risk patients. Osteoporosis is a common metabolic bone disease affecting up to 40% of postmenopausal women. It is often asymptomatic, and many fractures go unrecognized. FRAX is a tool that considers clinical risk factors and BMD to assess fracture risk. It is used to determine when treatment is needed, especially for patients with a T-score between -1.0 and -2.5 and a high fracture risk. FRAX has been validated in various countries and is available online. Bone mineral density is measured using dual x-ray absorptiometry, but it has limitations. It does not account for bone geometry or microarchitecture. Other factors, such as age, history of fractures, and lifestyle, also contribute to fracture risk. FRAX incorporates these factors to improve fracture risk prediction. Bone turnover markers, such as bone resorption and formation markers, are used to assess bone health and monitor treatment effectiveness. These markers can help identify patients at higher risk of fractures. However, FRAX may not accurately predict fracture risk in all age groups or for all patients. The article emphasizes the importance of combining clinical risk factors, BMD, and bone turnover markers to improve fracture risk assessment. It also highlights the limitations of FRAX, including potential inaccuracies in predicting fracture risk and the need for further research. Overall, the assessment of fracture risk is crucial for effective osteoporosis management and prevention of fractures.